放射性核素标记西妥昔单抗靶向诊断与治疗三阴性乳腺癌的研究
首发时间:2019-05-31
摘要:目的:分别用125I和177Lu标记西妥昔单抗在动物水平研究靶向性诊断与治疗三阴性乳腺癌的效果。方法:分别用125I和177Lu标记西妥昔单抗,通过荷三阴性乳腺癌(4T1)移植瘤裸鼠的SPECT/CT显像、体内分布与移植瘤抑制实验及HE染色和免疫组化分析检测核素治疗的效果。结果:荷瘤裸鼠尾静脉注射125I-Cetuximab后进行SPECT/CT显像,2 h肿瘤部位放射性达最高值,随后放射性迅速减少;尾静脉注射125I-Cetuximab后1 h时肿瘤部位放射性达最高,为(2.46±0.49)%, 8 h时降低到(0.81±0.53)%;治疗组体重与移植瘤大小无统计学意义的荷移植瘤裸鼠经177Lu-DOTA-Cetuximab治疗20天后,治疗组与生理盐水组之间的体重差异有显著统计学意义(P<0.01),且治疗组与生理盐水组的移植瘤体积差异有显著统计学意义(P<0.01),177Lu-DOTA-Cetuximab治疗的抑瘤率为(38.7±5.1)%。结论:西妥昔单抗作为EGFR高表达癌细胞的靶向性物质可与4T1细胞特异性结合,125I和177Lu发射的γ和β射线可应用于核医学显像诊断与治疗。
关键词: 放射医学 125I 177Lu 西妥昔单抗 三阴性乳腺癌 SPECT/CT
For information in English, please click here
Targeted diagnosis and treatment of triple-negative breast cancer with radionuclide labeled cetuximab
Abstract:Purpose: Cetuximab was labeled with 125I and 177Lu respectively, to study the effect of targeted diagnosis and treatment of triple-negative breast cancer at the animal level. Methods: Cetuximab was labeled with 125I and 177Lu respectively, to explore the effect of treatment by SPECT/CT imaging, in vivo distribution, xenograft inhibition assay, HE staining and immunohistochemical analysis of nuclide in nude mice bearing triple negative breast cancer (4T1). Results: The tumor-bearing nude mice were injected with 125I-Cetuximab for SPECT/CT imaging. The radioactivity reached the highest value at 2 h, and then the radioactivity decreased rapidly. The radioactivity of the tumor site reached the highest at 1 h after 125I-Cetuximab injection in the tail vein (2.46±0.49)%, and decreased to (0.81±0.53)% at 8 h. pre-treatment body weight and transplanted tumor size were not statistically significant. The transplanted nude mice were treated with 177Lu-DOTA-Cetuximab for 20 days, between the treatment group and the saline group. The difference in body weight was statistically significant (P<0.01), and there was a statistically significant difference in the volume of transplanted tumor between the treatment group and the saline group (P<0.01), and the tumor inhibition rate of 177Lu-DOTA-Cetuximab treatment (38.7±5.1)%. Conclusions: Cetuximab as a target substance for cancer cells with high expression of EGFR can specifically bind to 4T1 cells, and γ and β rays emitted by 125I and 177Lu can be used for diagnosis and treatment of nuclear medicine imaging.
Keywords: Radiology 125I 177Lu Cetuximab triple-negative breast cancer SPECT/CT
基金:
引用
No.****
动态公开评议
共计0人参与
勘误表
放射性核素标记西妥昔单抗靶向诊断与治疗三阴性乳腺癌的研究
评论
全部评论0/1000